McKesson Corporation with ticker code (MCK) now have 13 confirmed analysts covering the stock with the consensus suggesting a rating of ‘Buy’. The target price High/Low ranges between 455 and 376 calculating the average target price we see $430.15. Now with the previous closing price of $355.55 this indicates there is a potential upside of 21.0%. There is a 50 day moving average of $354.57 and the 200 day moving average is $360.77. The company has a market cap of $48,930m. You can visit the company’s website by visiting: https://www.mckesson.com
The potential market cap would be $59,196m based on the market consensus.
McKesson Corporation provides healthcare services in the United States and internationally. It operates through four segments: U.S. Pharmaceutical, International, Medical-Surgical Solutions, and Prescription Technology Solutions (RxTS). The U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar, and over-the-counter pharmaceutical drugs and other healthcare-related products. This segment also provides practice management, technology, clinical support, and business solutions to community-based oncology and other specialty practices; and consulting, outsourcing, technological, and other services, as well as sells financial, operational, and clinical solutions to pharmacies. The International segment offers distribution and services to wholesale, institutional, and retail customers in 13 European countries and Canada. The Medical-Surgical Solutions segment provides medical-surgical supply distribution, logistics, and other services to healthcare providers. The RxTS segment serves biopharma and life sciences partners and patients to address medication challenges for patients throughout their journeys; connects pharmacies, providers, payers, and biopharma companies to deliver innovative access and adherence solutions; and provides third-party logistics and wholesale distribution support solutions. McKesson Corporation was founded in 1833 and is headquartered in Irving, Texas.
The company has a dividend yield of 0.61% with the ex dividend date set at 28-2-2023 (DMY).
Other points of data to note are a P/E ratio of 16.42, revenue per share of 1906.41 and a 4.17% return on assets.
